COVID-19

The Drugs Controller General of India, DCGI, has given permission for the emergency use of 2 deoxyD-glucose, 2-DG medicine as an adjunct therapy in moderate to severe Covid-19 cases.

An anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) has been developed by Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy’s Laboratories (DRL), Hyderabad.

Institute of Life Sciences Bhubaneswar, an autonomous institute of the Department of Biotechnology, Ministry of Science & Technology, Government of India invites applications from Indian Nationals to join in the following positions coterminous with the project duration.

Project title : Anti-viral screening platform for viral diseases : with special reference to COVID-19.

Ballari Covid 19 Hospitals notification for Staff Nurse, Group D, Medical Officer, Pharmacist.

Post : Pharmacist

No of Posts : 18
Qualification : D.Pharm
Age Limit : upper age limit is 38 years
Salary : Rs.22000/-

Natco Pharma Limited has received Emergency Use approval for Baricitinib tablets, 1mg, 2mg and 4mg strengths from Central Drugs Standard Control Organization (CDSCO) in India. Baricitinib in combination with Remdesivir, is used for treatment of COVID-19 positive patients.

The National Institute of Immunology, New Delhi, is a leading research Institute in India with a long-standing reputation for scientific excellence. The institute is equipped with state-of-the-art infrastructure for pursuing research in immunology and allied sciences. The Institute also imparts vigorous long-term research training leading to a Ph.D degree.

Walk in Interview (Novel Corona Virus (Covid - 19) It is therefore announced that, in order to meet the status of Novel Corona Virus (Covid 19), management of Anand District Hospitals and Covid Care Centers and treatment of Corona Virus sufferers below.  The said posts have to be filled for three months with fixed honorarium.

Post : Junior Pharmacist

Biological E. Limited, a Hyderabad-based vaccine and pharmaceutical company announced that it has successfully completed the Phase I/II clinical trial of its COVID-19 subunit vaccine candidate in India and received the approval to start the Phase III clinical trial from the Central Drugs Standard Control Organization (CDSCO) - Subject Expert Committee (SEC).

Zydus Cadila announced that the company has received Restricted Emergency Use Approval from the Drug Controller General of India (DCGI) for the use of  Virafin, Pegylated Interferon alpha-2b (PegIFN) in treating moderate COVID-19 infection in adults. A single dose subcutaneous regimen of the antiviral Virafin will make the treatment more convenient for the patients. When administered early on during COVID, Virafin will help patients recover faster and avoid much of the complications.

COVID-19 needs no introduction. Last year, the disease, which is caused by the virus SARS-CoV-2, reached every continent across the globe. By the end of March 2021, there had been an estimated 128 million cases recorded with almost three million of these being fatal. As scientists' race to develop vaccines and politicians coordinate their distribution, fundamental research on what makes this virus so successful is also being carried out.